Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells

Cancer Letters

Volumn 268, Issue 2, 2008, Pages 225-232

  Kim, Jung Ae ^a   Cho, Kyoung Bin ^b   Kim, Mi Ra ^b   Park, Byung Chul ^a   Kim, Sang Kyum ^c   Lee, Moo Yeol ^d   Kang, Keon Wook ^b  

^a Yeungnam University   (South Korea)

^b Chosun University   (South Korea)

^c Chungnam National University   (South Korea)

^d Chonnam National University   (South Korea)

Author keywords

Adriamycin resistant breast cancer; Angiogenesis; HIF 1 ; VEGF

Indexed keywords

DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE B; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL STRAIN MCF 7; CHICK EMBRYO; CHORIOALLANTOIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEREGULATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS (GENETICS); VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 48549092906     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.050     Document Type: Article

References (38)

1. Fairchild C.R., Ivy S.P., Kao-Shan C.S., Whang-peng J., Rosen N., Isreal M.A., Melera P.W., Cowan K.H., and Goldsmith M.E. Isolation of amplified and overexpressed DNA sequences from adriamycin resistant human breast cancer cells. Cancer Res. 47 (1987) 5141-5148
2. Fairchild C.R., Moscow J.A., O'Brien E.E., and Cowan K.H. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. Mol. Pharmacol. 37 (1990) 801-809
3. Semenza G.L. Hypoxia, Clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 35 (2000) 71-103
4. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6 (2000) 389-395
5. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
6. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
7. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., Heim W., Berlin J., Holmgren E., Hambleton J., Novotny W.F., and Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 23 (2005) 3502-3508
8. Schneider B.P., and Sledge G.W. Drug insight:VEGF as a therapeutic target for breast cancer. Nat. Clin. Pract. Oncol. 4 (2007) 181-189
9. Auerbach R., Kubai L., Knighton D., and Folkman J.A. A simple procedure for the long-term cultivation of chicken embryos. Dev. Biol. 41 (1974) 391-394
10. Colman R.W., Pixley R.A., Sainz I.M., Song J.S., Isordia-Salas I., Muhamed S.N., Powell Jr. J.A., and Mousa S.A. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J. Thromb. Haemost. 1 (2003) 164-170
11. Lee J.Y., Han C.Y., Yang J.W., Smith C., Kim S.K., Lee E.Y., Kim S.G., and Kang K.W. Induction of glutathione transferase in insulin-like growth factor type I receptor-overexpressed hepatoma cells. Mol. Pharmacol. 72 (2007) 1082-1093
12. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21 (2000) 505-515
13. Shi Q., Le X., Abbruzzese J.L., Peng Z., Qian C.N., Tang H., Xiong Q., Wang B., Li X.C., and Xie K. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 61 (2001) 4143-4154
14. Chang H.J., Park J.S., Kim M.H., Hong M.H., Kim K.M., Kim S.M., Shin B.A., Ahn B.W., and Jung Y.D. Extracellular signal-regulated kinases and AP-1 mediate the up-regulation of vascular endothelial growth factor by PDGF in human vascular smooth muscle cells. Int. J. Oncol. 28 (2006) 135-141
15. Li Y.Q., Tao K.S., Ren N., and Wangm Y.H. Effect of c-fos antisense probe on prostaglandin E2-induced upregulation of vascular endothelial growth factor mRNA in human liver cancer cells. World J. Gastroenterol. 11 (2005) 4427-4430
16. Textor B., Sator-Schmitt M., Richter K.H., Angel P., and Schorpp-Kistner M. c-Jun and JunB are essential for hypoglycemia-mediated VEGF induction. Ann. NY Acad. Sci. 1091 (2006) 310-318
17. Mazure N.M., Chen E.Y., Laderoute K.R., and Giaccia A.J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90 (1997) 3322-3331
18. Gao N., Shen L., Zhang Z., Leonard S.S., He H., Zhang X.G., Shi X., and Jiang B.H. Arsenite induces HIF-1alpha and VEGF through PI3K Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol. Cell. Biochem. 255 (2004) 33-45
19. 2 -induced HIF-1alpha expression correlates with proliferation and apoptosis in MKN-1 cells: a possible role for the PI3K/Akt pathway. Int. J. Oncol. 29 (2006) 549-555
20. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
21. Flügel D., Görlach A., Michiels C., and Kietzmann T. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol. Cell. Biol. 27 (2007) 3253-3265
22. Ribatti D., and Vacca A. Models for studying angiogenesis in vivo. Int. J. Biol. Markers 14 (1999) 207-213
23. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., and Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (1997) 4593-4599
24. Sun L., Liang C., Shirazian S., Zhou Y., Miller T., Cui J., Fukuda J.Y., Chu J.Y., Nematalla A., Wang X., Chen H., Sistla A., Luu T.C., Tang F., Wei J., and Tang C. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46 (2003) 1116-1119
25. Clemons M., Danson S., and Howell A. Tamoxifen ('Nolvadex'): a review. Cancer Treat. Rev. 28 (2002) 165-180
26. Gottardis M.M., and Jordan V.C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48 (1988) 5183-5187
27. Politi P.M., Arnold S.T., Felsted R.L., and Sinha B.K. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. Mol. Pharmacol. 37 (1990) 790-796
28. Yu S.T., Chen T.M., Tseng S.Y., and Chen Y.H. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem. Biophys. Res. Commun. 358 (2007) 79-84
29. Ameyar M., Shatrov V., Bouquet C., Capoulade C., Cai Z.Z., Stancou R., Badie C., Haddada H., and Chouaib S. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 18 (1999) 5464-5472
30. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., Dickler M., Overmoyer B.A., Reimann J.D., Sing A.P., Langmuir V., and Rugo H.S. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23 (2005) 792-799
31. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8 (2002) S62-S67
32. Xie K., Wei D., Shi Q., and Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 15 (2004) 297-324
33. Lee J.W., Bae S.H., Jeong J.W., Kim S.H., and Kim K.W. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp. Mol. Med. 36 (2004) 1-12
34. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., and Obberghen E.V. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277 (2002) 27975-27981
35. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., and Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277 (2002) 38205-38211
36. Sodhi A., Montaner S., Miyazaki H., and Gutkind J.S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem. Biophys. Res. Commun. 287 (2001) 292-300
37. Harris A.L., Zhang H., Moghaddam A., Fox S., Scott P., Pattison A., Gatter K., Stratford I., and Bicknell R. Breast cancer angiogenesis-new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Res. Treat. 38 (1996) 97-108
38. McLeskey S.W., Zhang L., Kharbanda S., Kurebayashi J., Lippman M.E., Dickson R.B., and Kern F.G. Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res. Treat. 39 (1996) 103-117